- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03320707
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
September 4, 2019 updated by: Janssen Research & Development, LLC
A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
The purpose of this study is to assess the safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants and to determine whether premedication with corticosteroids is required to improve the tolerability of SC administration of daratumumab in healthy participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85283
- Celerion
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have a body weight in the range of 50 to 100 kilogram (kg), inclusive, and have a body mass index (BMI) of 19 to 30 kilogram per meter square (kg/m^2), inclusive, at screening and Day -1
- Must be otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and Day -1
- Must be otherwise healthy on the basis of clinical laboratory tests performed at screening and Day -1
- A woman must not be of childbearing potential
- Must be a non-smoker or tobacco user or 3 months prior to screening
Exclusion Criteria:
- Pregnant or breastfeeding while enrolled in this study or within 20 weeks after the dose of study treatment
- History of or currently has any clinically significant medical illness or medical disorders the investigator considers significant, including, but not limited to immune deficiency state, liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Has a history of malignancy before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered cured with minimal risk of recurrence
- Active acute or chronic infection (including chronic recurrent or invasive candidiasis) or diagnosed latent infection
- Has had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening and/or plan to receive a BCG vaccine within 12 months after the administration of study treatment
- Has experienced a recent single dermatomal herpes zoster eruption within the past 6 months
- Has a history of multi-dermatomal herpes zoster or central nervous system (CNS) zoster within the past 5 years
- Has received prescription medications within 14 days prior to study treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Daratumumab
Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts.
Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort.
Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
|
Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
Other Names:
Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
|
Placebo Comparator: Placebo
Participants will receive placebo as a single SC dose in each of first 7 cohorts.
|
Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants With Treatment-Emergent Adverse Event (TEAEs) by Severity Through Day 141 Versus Placebo
Time Frame: Up to Day 141
|
The safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants will be assessed.
|
Up to Day 141
|
Proportion of Participants With TEAEs by Serious Adverse Events (SAEs) Through Day 141 Versus Placebo
Time Frame: Up to Day 141
|
The safety and tolerability of daratumumab following a single subcutaneous (SC) administration in healthy participants will be assessed.
|
Up to Day 141
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Day 1 predose through Day 141
|
Cmax is the maximum observed plasma concentration.
|
Day 1 predose through Day 141
|
Time to the Maximum Observed Plasma Concentration (Tmax)
Time Frame: Day 1 predose through Day 141
|
Tmax is defined as actual sampling time to reach maximum observed plasma concentration.
|
Day 1 predose through Day 141
|
Area Under the Plasma Concentration-time Curve From Time Zero to the Time Corresponding to the Last Quantifiable Serum Concentration (AUC [0-last])
Time Frame: Day 1 predose through Day 141
|
AUC (0-last) is the area under the plasma concentration-time curve from time zero to the time corresponding to the last quantifiable serum concentration.
|
Day 1 predose through Day 141
|
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity With Extrapolation of the Terminal Phase (AUC[0- infinity])
Time Frame: Day 1 predose through Day 141
|
AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinity with extrapolation of the terminal phase, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
|
Day 1 predose through Day 141
|
Number of Participants With Anti-daratumumab Antibodies
Time Frame: Day 1 predose through Day 141
|
Number of participants who test positive for anti-daratumumab antibodies will be reported.
|
Day 1 predose through Day 141
|
Number of Participants With Anti-recombinant Human Hyaluronidase (rHuPH20) Antibodies
Time Frame: Day 1 predose through Day 141
|
Number of participants who test positive for anti-rHuPH20 antibodies will be reported.
|
Day 1 predose through Day 141
|
Percentage of CD38 Expression Levels and CD38 Expressing Cell Counts Measured by Flow Cytometry
Time Frame: Day 1 predose through Day 141
|
The cluster of differentiation (CD) 38 expression levels and CD38 expressing cell counts, as measured by flow cytometry, will be summarized.
|
Day 1 predose through Day 141
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2017
Primary Completion (Actual)
August 27, 2019
Study Completion (Actual)
August 27, 2019
Study Registration Dates
First Submitted
October 11, 2017
First Submitted That Met QC Criteria
October 24, 2017
First Posted (Actual)
October 25, 2017
Study Record Updates
Last Update Posted (Actual)
September 6, 2019
Last Update Submitted That Met QC Criteria
September 4, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108356
- 54767414EDI1001 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Lancaster UniversityRecruiting
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Daratumumab
-
Janssen Research & Development, LLCActive, not recruitingSmoldering Multiple MyelomaUnited States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
-
Boston Medical CenterJanssen PharmaceuticalsCompleted
-
National Cancer Institute (NCI)RecruitingLymphoma, Primary EffusionUnited States
-
Ostfold Hospital TrustOdense University Hospital; Oslo University Hospital; Haukeland University Hospital and other collaboratorsActive, not recruiting
-
Ronald WittelesCompletedHeart Transplant Failure and Rejection | AllosensitizationUnited States
-
University of ArkansasJanssen Scientific Affairs, LLCRecruiting
-
Incyte CorporationTerminatedRelapsed or Refractory Multiple MyelomaUnited States, Spain, Germany
-
Marc L Gordon, MDJanssen Scientific Affairs, LLCCompletedAlzheimer DiseaseUnited States
-
Hoffmann-La RocheCompletedMultiple MyelomaUnited States, Australia, United Kingdom
-
Charite University, Berlin, GermanyJanssen-Cilag G.m.b.H; Labor Berlin-Charité Vivantes G.m.b.H; Deutsches Rheuma-Forschungszentrum... and other collaboratorsNot yet recruiting